March 17, 2021
Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Society’s 2021 Annual Meeting
Media
March 17, 2021
Targovax ASA announces new member of the Board
March 17, 2021
Orexo continues to strengthen IP rights for ZUBSOLV®
March 16, 2021
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
March 16, 2021
Orexo publishes prospectus and applies for admission to trading of corporate bonds
March 15, 2021
Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO®
March 11, 2021
Vicore Pharma’s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease
March 10, 2021
Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million)
March 09, 2021
Targovax granted US Patent for ONCOS-102 in combination with checkpoint inhibitors
March 08, 2021
Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma